Discover insights from Autolus Therapeutics' Q2 2025 earnings call. Explore revenue growth, AUCATZYL expansion, and strategic plans for U.S. and EU markets.

Q2 2025 net revenue of $25.9 million, driven by product net revenue of $21.8 million Completed sale of PRV for $150.0 million, bolstering the balance sheet as the Company executes on its commercial ...